(This Feb. 10 story has been refiled to say 'LOEs (loss of exclusivity),' not 'LOEs (levels of evidence),' in paragraph 13) ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...